Vera Therapeutics Files 8-K for Reg FD Disclosure

Ticker: VERA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1831828

Vera Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyVera Therapeutics, INC. (VERA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: Regulation-FD, corporate-filing, disclosure

TL;DR

**Vera Therapeutics just dropped an 8-K for Reg FD, watch for upcoming news!**

AI Summary

Vera Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibits. This filing indicates that the company is providing information that was not previously public, likely related to an upcoming event or announcement. For investors, this matters because Regulation FD disclosures often precede significant news, which could impact the stock price of VERA, either positively or negatively, depending on the nature of the information shared.

Why It Matters

This filing signals that Vera Therapeutics is making new, material information public, which could influence investor perception and the company's stock performance. Investors should monitor for subsequent announcements to understand the full implications.

Risk Assessment

Risk Level: medium — The risk is medium because Regulation FD disclosures can precede either positive or negative news, creating uncertainty for investors until the specific information is revealed.

Analyst Insight

A smart investor would closely monitor Vera Therapeutics' news releases and subsequent SEC filings in the coming days or weeks to understand the specific information disclosed under Regulation FD, as this will clarify the potential impact on the stock.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Vera Therapeutics, Inc.?

The primary purpose of this 8-K filing by Vera Therapeutics, Inc. is to disclose information under Regulation FD and to file financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.

What is the trading symbol and exchange for Vera Therapeutics, Inc.'s Class A common stock?

Vera Therapeutics, Inc.'s Class A common stock, with a $0.001 par value per share, trades under the symbol 'VERA' on The Nasdaq Stock Market LLC, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address of Vera Therapeutics, Inc.?

The business address of Vera Therapeutics, Inc. is 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005, as detailed in the 'BUSINESS ADDRESS' section of the filing.

Is Vera Therapeutics, Inc. considered an emerging growth company according to this filing?

The filing indicates with a '☐' (unchecked box) next to 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933', suggesting that Vera Therapeutics, Inc. is not currently identifying itself as an emerging growth company for the purposes of this report.

Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-08 08:03:08

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Vera Therapeutics, Inc. (the "Company") released an updated corporate presentation (the "Corporate Presentation"). The Corporate Presentation is available on the Company's website, and a copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. For important information about forward-looking statements, see the slide titled "Forward Looking Statements" in Exhibit 99.1 attached hereto. The information set forth in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Slide presentation entitled "Corporate Presentation". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: January 8, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing